Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

UTHR

United Therapeutics Corp

Nov 28 • 02:02PM ET

229.49

Dollar change -1.61
Percentage change -0.70	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	12.64	EPS (ttm)	18.15	Insider Own	2.55%	Shs Outstand	46.03M	Perf Week	0.22%
Market Cap	10.78B	Forward P/E	10.65	EPS next Y	21.56	Insider Trans	-5.44%	Shs Float	45.80M	Perf Month	4.68%
Income	899.80M	PEG	1.30	EPS next Q	4.10	Inst Own	94.34%	Short Float / Ratio	2.48% / 4.34	Perf Quarter	-0.02%
Sales	2.20B	P/S	4.89	EPS this Y	31.11%	Inst Trans	1.02%	Short Interest	1.13M	Perf Half Y	11.84%
Book/sh	121.58	P/B	1.89	EPS next Y	9.61%	ROA	14.05%	Target Price	286.96	Perf Year	-14.39%
Cash/sh	61.19	P/C	3.75	EPS next 5Y	9.70%	ROE	17.52%	52W Range	204.44 - 283.09	Perf YTD	-17.48%
Dividend	-	P/FCF	14.30	EPS past 5Y	10.00%	ROI	14.48%	52W High	-18.93%	Beta	0.56
Dividend %	-	Quick Ratio	4.51	Sales past 5Y	2.85%	Gross Margin	88.87%	52W Low	12.25%	ATR	4.52
Employees	985	Current Ratio	4.65	Sales Q/Q	18.10%	Oper. Margin	49.92%	RSI (14)	53.18	Volatility	1.37% 2.37%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	9.58%	Profit Margin	40.82%	Rel Volume	0.46	Prev Close	231.10
Shortable	Yes	LT Debt/Eq	0.09	Earnings	Nov 01 BMO	Payout	0.00%	Avg Volume	261.15K	Price	229.49
Recom	1.64	SMA20	1.10%	SMA50	1.12%	SMA200	0.75%	Volume	84,790	Change	-0.70%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125
Mar-10-20	Upgrade	Jefferies	Hold → Buy	$123
Feb-27-20	Upgrade	Cowen	Market Perform → Outperform	$119 → $145
Jan-31-20	Upgrade	JP Morgan	Neutral → Overweight	$120
Dec-03-19	Initiated	BofA/Merrill	Underperform
Aug-01-19	Upgrade	Ladenburg Thalmann	Neutral → Buy	$103 → $106
Aug-01-19	Upgrade	Jefferies	Underperform → Hold	$90
Jul-01-19	Upgrade	Credit Suisse	Neutral → Outperform	$98 → $101
May-17-19	Upgrade	UBS	Sell → Neutral	$115 → $94
May-09-19	Upgrade	Credit Suisse	Underperform → Neutral	$98

Show Previous Ratings

Nov-24-23 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-18-23 07:03AM	Insider Sell Alert: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United ... (GuruFocus.com)
Nov-14-23 04:05PM	Miromatrix Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
03:49AM	Loading…
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 12:30PM	3d Systems (DDD) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-06-23 12:19AM	Six Flags' pact with Cedar Fair; Disney's Hulu buy: 4 big deal reports (Investing.com)
Nov-03-23 11:43PM	EVP & General Counsel Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)
Nov-02-23 02:34PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
01:15PM	United Therapeutics Corporation (NASDAQ:UTHR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-01-23 11:00PM	Q3 2023 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
09:35AM	United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates (Zacks)
09:30AM	United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:21AM	United Therapeutics Corp (UTHR) Reports 18% YoY Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	Loading…
07:15AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates (Zacks)
06:04AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	United Therapeutics Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-31-23 06:05AM	United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis (Business Wire)
06:00AM	United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023 (Business Wire)
Oct-30-23 06:05AM	United Therapeutics to Acquire Miromatrix Medical (GlobeNewswire)
Oct-26-23 10:02AM	ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-25-23 10:02AM	Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for (Zacks)
06:00AM	United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023 (Business Wire)
Oct-20-23 09:55PM	EVP & General Counsel Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)
Oct-17-23 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Oct-02-23 11:34AM	FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease (Zacks)
Sep-28-23 10:56AM	3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity (Zacks)
Sep-22-23 11:01PM	EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)
02:15PM	United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs (Business Wire)
04:15PM	Loading…
Sep-20-23 04:15PM	Bullet Proof Your Portfolio: 3 Must-Have Defensive Stocks for 2023 (InvestorPlace)
Sep-12-23 06:00AM	United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report (Business Wire)
Sep-09-23 01:03AM	EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics Corp (GuruFocus.com)
Sep-01-23 06:00AM	United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-20-23 10:00AM	Looking for an Alternative to ESG Investing? Heres One Possibility (The Wall Street Journal)
Aug-08-23 11:33AM	Q2 2023 MannKind Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-04-23 12:16PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
07:28AM	12 Best Biotech ETFs To Buy (Insider Monkey)
Aug-02-23 12:29PM	United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates (Zacks)
09:30AM	United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:15AM	United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:06AM	United Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:00AM	United Therapeutics Corporation Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-26-23 01:23PM	If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names (InvestorPlace)
06:00AM	United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023 (Business Wire)
Jul-25-23 02:37PM	Liquidia stock drops after setback in United Therapeutics dispute (American City Business Journals)
08:25AM	Silver Spring's United Therapeutics claims victory in patent infringement suit against Liquidia (American City Business Journals)
Jul-24-23 11:45AM	United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation (Business Wire)
Jul-20-23 07:20AM	Technical Assessment: Neutral in the Intermediate-Term (Argus Research)
Jul-13-23 06:56AM	Analyst Report: United Therapeutics Corp (Argus Research)
06:41AM	Market Digest: UTHR (Argus Research)
Jul-10-23 09:47AM	United Therapeutics (NASDAQ:UTHR) sheds 5.3% this week, as yearly returns fall more in line with earnings growth (Simply Wall St.) +5.34%
Jun-14-23 06:00AM	United Therapeutics Unveils Net Zero Energy Distribution Center (Business Wire)
Jun-08-23 11:30AM	Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report? (Zacks)
May-25-23 04:03AM	14 Best Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
May-19-23 08:35AM	Billionaire Jim Simons 2023 Portfolio: Top 15 Stock Picks (Insider Monkey)
May-05-23 03:13PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
May-04-23 09:04AM	United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss (Zacks)
May-03-23 11:11PM	Q1 2023 United Therapeutics Corp Earnings Call (Thomson Reuters StreetEvents)
04:52PM	Why United Therapeutics Shares Are Falling Today (Benzinga)
09:30AM	Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings (Zacks)
07:15AM	United Therapeutics (UTHR) Q1 Earnings Beat Estimates (Zacks)
06:06AM	United Therapeutics: Q1 Earnings Snapshot (AP Finance)
06:00AM	United Therapeutics Corporation Reports First Quarter 2023 Financial Results (Business Wire)
Apr-27-23 10:03AM	Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-23 10:02AM	Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline (Zacks)
06:00AM	United Therapeutics Corporation to Report First Quarter 2023 Financial Results Before the Market Opens on Wednesday, May 3, 2023 (Business Wire)
Apr-24-23 06:59AM	United Therapeutics Corporation's (NASDAQ:UTHR) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? (Simply Wall St.)
Apr-19-23 07:22PM	7 Biotech Stocks That Could Cure Your Portfolio Woes (InvestorPlace)
Apr-18-23 06:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at Upcoming Scientific Meetings (Business Wire)
Mar-27-23 11:02AM	Here's Why We Think United Therapeutics (NASDAQ:UTHR) Is Well Worth Watching (Simply Wall St.)
Mar-24-23 11:30AM	United Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-17-23 03:22AM	Q4 2022 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-07-23 07:12PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
Mar-06-23 04:30PM	United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Feb-28-23 05:57PM	Analyst Report: United Therapeutics Corporation (Morningstar Research)
06:00AM	United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-27-23 07:56AM	Weekly Stock List (Argus Research)
Feb-23-23 12:06PM	United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates (Zacks)
10:50AM	13 High Growth Pharma Stocks that are Profitable (Insider Monkey)
06:12AM	United Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Feb-22-23 07:15AM	United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates (Zacks)
06:00AM	United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
05:30AM	Why the 2023 rally might be in trouble: Morning Brief (Yahoo Finance)
Feb-21-23 11:09AM	Should You Buy United Therapeutics (UTHR) Ahead of Earnings? (Zacks)
Feb-16-23 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-15-23 06:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2022 Financial Results Before the Market Opens on Wednesday, February 22, 2023 (Business Wire)
Feb-13-23 09:00AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Feb-05-23 08:49PM	Decision moves Liquidia, United Therapeutics patent dispute toward resolution (American City Business Journals)
Jan-30-23 07:55AM	Those who invested in United Therapeutics (NASDAQ:UTHR) three years ago are up 172% (Simply Wall St.)
Jan-27-23 11:40AM	UTHR vs. ZTS: Which Stock Is the Better Value Option? (Zacks)
Jan-25-23 10:37AM	12 Cheap Biotech Stocks To Buy (Insider Monkey)
Jan-21-23 06:34PM	10 Best Healthcare Stocks For Recession (Insider Monkey)
Jan-19-23 09:35AM	After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR) (Zacks)
Jan-11-23 07:10AM	Analyst Report: United Therapeutics Corp (Argus Research)
06:55AM	Market Digest: UTHR, LULU (Argus Research)
Jan-09-23 10:01PM	Liquidia inks $100M financing agreement amid patent dispute (American City Business Journals)
11:40AM	UTHR or ESALY: Which Is the Better Value Stock Right Now? (Zacks)
Jan-06-23 06:50PM	3 Biotech Companies to Watch in 2023 (InvestorPlace)
07:29AM	United Therapeutics Corporation's (NASDAQ:UTHR) Intrinsic Value Is Potentially 98% Above Its Share Price (Simply Wall St.)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 16	Option Exercise	117.76	6,000	706,560	42,599	Nov 17 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 16	Sale	226.60	6,000	1,359,593	36,599	Nov 17 04:30 PM
PATUSKY CHRISTOPHER	Director	Nov 07	Option Exercise	88.03	2,000	176,060	3,684	Nov 08 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 02	Option Exercise	117.76	6,000	706,560	42,599	Nov 03 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Nov 02	Sale	225.76	6,000	1,354,554	36,599	Nov 03 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 19	Option Exercise	117.76	6,000	706,560	42,599	Oct 20 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 19	Sale	225.43	6,000	1,352,591	36,599	Oct 20 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 05	Option Exercise	117.76	6,000	706,560	42,599	Oct 10 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Oct 05	Sale	223.82	6,000	1,342,923	36,599	Oct 10 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 21	Option Exercise	117.76	6,000	706,560	42,599	Sep 22 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 21	Sale	222.19	6,000	1,333,150	36,599	Sep 22 04:30 PM
Mesa Nilda	Director	Sep 13	Sale	222.36	383	85,164	6,303	Sep 15 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 07	Option Exercise	117.76	6,000	706,560	42,599	Sep 08 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Sep 07	Sale	222.98	6,000	1,337,905	36,599	Sep 08 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Aug 17	Option Exercise	117.76	6,000	706,560	42,599	Aug 18 04:30 PM
PATUSKY CHRISTOPHER	Director	Aug 17	Option Exercise	88.03	2,000	176,060	3,684	Aug 18 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Aug 17	Sale	229.54	6,000	1,377,265	36,599	Aug 18 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Aug 03	Option Exercise	117.76	6,000	706,560	42,599	Aug 04 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Aug 03	Sale	236.25	6,000	1,417,470	36,599	Aug 04 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jul 20	Option Exercise	120.26	2,500	300,650	39,099	Jul 24 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jul 20	Sale	243.87	2,500	609,675	36,599	Jul 24 04:30 PM
SULLIVAN LOUIS W	Director	Jul 07	Option Exercise	0.00	880	0	13,060	Jul 07 04:30 PM
Thompson Tommy G	Director	Jul 07	Option Exercise	0.00	880	0	8,480	Jul 07 04:30 PM
Olian Judy D.	Director	Jul 07	Option Exercise	0.00	1,750	0	8,255	Jul 07 04:30 PM
Mesa Nilda	Director	Jul 07	Option Exercise	0.00	880	0	6,686	Jul 07 04:30 PM
KURZWEIL RAY	Director	Jul 07	Option Exercise	0.00	880	0	11,180	Jul 07 04:30 PM
Klein Katherine J	Director	Jul 07	Option Exercise	0.00	880	0	3,640	Jul 07 04:30 PM
DWEK RAYMOND	Director	Jul 07	Option Exercise	0.00	1,750	0	1,750	Jul 07 04:30 PM
Giltner Richard	Director	Jul 07	Option Exercise	0.00	1,750	0	15,620	Jul 07 04:30 PM
CAUSEY CHRISTOPHER	Director	Jul 07	Option Exercise	0.00	1,750	0	4,585	Jul 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jul 06	Option Exercise	120.26	6,000	721,560	42,599	Jul 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jul 06	Sale	215.19	6,000	1,291,165	36,599	Jul 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jun 15	Option Exercise	120.26	6,000	721,560	42,599	Jun 15 05:23 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jun 15	Sale	227.77	6,000	1,366,634	36,599	Jun 15 05:23 PM
Thompson Tommy G	Director	Jun 13	Option Exercise	88.03	1,000	88,030	8,600	Jun 14 04:30 PM
Thompson Tommy G	Director	Jun 02	Option Exercise	88.03	1,000	88,030	8,600	Jun 05 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jun 01	Option Exercise	120.26	6,000	721,560	42,599	Jun 01 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jun 01	Sale	209.11	6,000	1,254,677	36,599	Jun 01 04:30 PM
Giltner Richard	Director	May 22	Option Exercise	63.90	5,000	319,500	18,870	May 23 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 18	Option Exercise	120.26	6,000	721,560	42,599	May 18 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 18	Sale	214.58	6,000	1,287,473	36,599	May 18 04:30 PM
PATUSKY CHRISTOPHER	Director	May 10	Option Exercise	88.03	2,000	176,060	3,684	May 11 04:30 PM
Mesa Nilda	Director	May 05	Sale	214.81	374	80,337	5,806	May 08 05:16 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 04	Option Exercise	120.26	6,000	721,560	42,599	May 04 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	May 04	Sale	215.82	6,000	1,294,903	36,599	May 04 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 02	Option Exercise	113.08	8,000	904,640	8,130	May 03 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 02	Sale	228.59	8,000	1,828,685	130	May 03 04:31 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 01	Option Exercise	113.08	8,000	904,640	8,130	May 02 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	May 01	Sale	231.40	8,000	1,851,202	130	May 02 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 28	Option Exercise	113.08	8,000	904,640	8,130	May 02 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 28	Sale	229.32	8,000	1,834,584	130	May 02 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 27	Option Exercise	113.08	8,000	904,640	8,130	Apr 28 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 27	Sale	226.50	8,000	1,812,022	130	Apr 28 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 26	Option Exercise	113.08	8,000	904,640	8,130	Apr 28 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 26	Sale	226.01	8,000	1,808,056	130	Apr 28 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 25	Option Exercise	113.08	8,000	904,640	8,130	Apr 26 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 25	Sale	226.04	8,000	1,808,313	130	Apr 26 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 24	Option Exercise	113.08	8,000	904,640	8,130	Apr 26 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 24	Sale	228.64	8,000	1,829,145	130	Apr 26 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 21	Option Exercise	113.08	8,000	904,640	8,130	Apr 24 04:30 PM
DWEK RAYMOND	Director	Apr 21	Option Exercise	63.90	2,000	127,800	2,000	Apr 24 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 21	Sale	228.82	8,000	1,830,557	130	Apr 24 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 20	Option Exercise	113.08	8,000	904,640	8,130	Apr 24 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 20	Option Exercise	120.26	6,000	721,560	42,599	Apr 20 05:00 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 20	Sale	224.90	8,000	1,799,227	130	Apr 24 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 20	Sale	223.96	6,000	1,343,755	36,599	Apr 20 05:00 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 19	Option Exercise	113.08	8,000	904,640	8,130	Apr 20 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 19	Sale	226.12	8,000	1,808,988	130	Apr 20 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 18	Option Exercise	113.08	8,000	904,640	8,130	Apr 20 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 18	Sale	226.78	8,000	1,814,271	130	Apr 20 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 17	Option Exercise	113.08	8,000	904,640	8,130	Apr 18 04:33 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 17	Sale	230.47	8,000	1,843,763	130	Apr 18 04:33 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 14	Option Exercise	113.08	8,000	904,640	8,130	Apr 18 04:33 PM
DWEK RAYMOND	Director	Apr 14	Option Exercise	63.90	2,000	127,800	2,000	Apr 18 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 14	Sale	228.48	8,000	1,827,876	130	Apr 18 04:33 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 13	Option Exercise	113.08	8,000	904,640	8,130	Apr 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 13	Sale	230.69	8,000	1,845,541	130	Apr 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 12	Option Exercise	113.08	8,000	904,640	8,130	Apr 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 12	Sale	227.15	8,000	1,817,199	130	Apr 14 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 11	Option Exercise	113.08	8,000	904,640	8,130	Apr 12 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 11	Sale	225.57	8,000	1,804,555	130	Apr 12 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 10	Option Exercise	113.08	8,000	904,640	8,130	Apr 12 04:30 PM
DWEK RAYMOND	Director	Apr 10	Option Exercise	63.90	3,000	191,700	3,000	Apr 12 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 10	Sale	224.21	8,000	1,793,684	130	Apr 12 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 06	Option Exercise	113.08	8,000	904,640	8,130	Apr 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 06	Option Exercise	120.26	6,000	721,560	42,599	Apr 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 06	Sale	229.12	8,000	1,832,925	130	Apr 07 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Apr 06	Sale	232.79	6,000	1,396,755	36,599	Apr 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 05	Option Exercise	113.08	8,000	904,640	8,130	Apr 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 05	Sale	231.35	8,000	1,850,776	130	Apr 07 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 04	Option Exercise	113.08	8,000	904,640	8,130	Apr 05 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 04	Sale	226.26	8,000	1,810,064	130	Apr 05 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 03	Option Exercise	113.08	8,000	904,640	8,130	Apr 05 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Apr 03	Sale	225.04	8,000	1,800,327	130	Apr 05 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 31	Option Exercise	113.08	8,000	904,640	8,130	Apr 03 04:51 PM
Thompson Tommy G	Director	Mar 31	Option Exercise	63.90	2,500	159,750	10,100	Apr 03 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 31	Sale	221.53	8,000	1,772,202	130	Apr 03 04:51 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 30	Option Exercise	113.08	8,000	904,640	8,130	Mar 31 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 30	Sale	217.14	8,000	1,737,091	130	Mar 31 04:30 PM
ROTHBLATT MARTINE A	CHAIRPERSON & CEO	Mar 29	Option Exercise	113.08	8,000	904,640	8,130	Mar 31 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UTHR

United Therapeutics Corp

Upgrade your FINVIZ experience